{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:16:03Z","timestamp":1788196563545,"version":"build-2803163510"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study aims to analyze the adverse events (AEs) related to the use of growth hormone (GH) drugs in children through mining the FDA adverse event reporting system (FAERS) database, and provide references for clinical medication safety. Data on children under 18 years of age from the FAERS database, covering the first quarter of 2004 to the first quarter of 2024, were extracted via the OpenVigil 2.1 tool. The reporting odds ratio was employed to analyze AE signals related to GHs. A total of 10,559 AE reports for children using GHs were obtained, revealing 361 risk signals across 20 organ systems. The top 5 system organ categories on the basis of the number of reports were general disorders and administration site conditions (33.4%), investigations (19.97%), musculoskeletal and connective tissue disorders (13.47%), nervous system disorders (13.06%), and metabolism and nutrition disorders (3.55%). Among the positive signals not mentioned in the product labeling, the top 5 were elevated blood urea nitrogen\/creatinine ratio, increased bone density, decreased vitamin D, sleep apnea syndrome, and papilloedema. The findings align with known AEs (e.g., injection site reactions, headaches) but also reveal unreported risks, emphasizing gaps in current labeling. High signal intensity for musculoskeletal and neurological events underscores the need for targeted monitoring. While tumor-related reports (3.28%) were noted, existing databases suggest no causal link, highlighting the limitations of FAERS in establishing causality. Racial bias in reporting (predominantly from the US) and voluntary reporting biases may affect generalizability. The signal intensity associated with muscle, skeletal, and neurological abnormalities in children via GHs is relatively high. Continuous monitoring and enhanced medication oversight are necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049264","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:02:39Z","timestamp":1781600559000},"page":"e49264","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Signal mining and analysis of adverse events in children using growth hormones: A retrospective real-world study based on FAERS"],"prefix":"10.1097","volume":"105","author":[{"given":"Wan","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Jiangsu Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Jiangsu Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3797-8973","authenticated-orcid":false,"given":"Yao","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Jiangsu Suzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260831","first-page":"29","article-title":"Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and turner syndrome (TS) in a tertiary care center.","volume":"91","author":"Shaikh","year":"2020","journal-title":"Acta Biomed"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502231","article-title":"Diagnosis, genetics, and therapy of short stature in children: international perspective.","volume":"92","author":"Collett-Solberg","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrendo.2018.22","article-title":"Growth hormone-past, present and future.","volume":"14","author":"Ranke","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.yapd.2022.03.005","article-title":"Clinical indications for growth hormone therapy.","volume":"69","author":"Danowitz","year":"2022","journal-title":"Adv Pediatr"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41581-019-0161-4","article-title":"Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.","volume":"15","author":"Drube","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/bs.pmbts.2015.10.008","article-title":"Effects of growth hormone on bone.","volume":"138","author":"Tritos","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children.","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(99)04055-6","article-title":"Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.","volume":"355","author":"Cutfield","year":"2000","journal-title":"Lancet"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/clinem\/dgad039","article-title":"Long-term pegylated GH for children with GH deficiency: a large, prospective, real-world study.","volume":"108","author":"Hou","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1210\/clinem\/dgab746","article-title":"Approach to the patient: safety of growth hormone replacement in children and adolescents.","volume":"107","author":"Bamba","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-20260831","first-page":"60","article-title":"Metabolic consequences of growth hormone treatment in paediatric practice.","volume":"53","author":"Saenger","year":"2000","journal-title":"Horm Res"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system.","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"1256649","DOI":"10.3389\/fphar.2024.1256649","article-title":"Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system.","volume":"15","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"key":"R15-20260831","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"d1248","DOI":"10.1136\/bmj.d1248","article-title":"Growth hormone in children with idiopathic short stature.","volume":"342","author":"Kerstin","year":"2011","journal-title":"BMJ"},{"key":"R17-20260831","first-page":"41","article-title":"Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database.","volume":"68","author":"Darendeliler","year":"2007","journal-title":"Horm Res"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(02)09561-2","article-title":"Risk of cancer after growth-hormone treatment.","volume":"360","author":"Giovannucci","year":"2002","journal-title":"Lancet"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2010.02.028","article-title":"Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database).","volume":"157","author":"Wilton","year":"2010","journal-title":"J Pediatr"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1080\/08035250600577889","article-title":"Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database).","volume":"95","author":"Darendeliler","year":"2006","journal-title":"Acta Paediatr"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/jc.2018-01189","article-title":"Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program.","volume":"104","author":"Child","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"P35","DOI":"10.1530\/EJE-21-1186","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2352-4642(24)00127-5","article-title":"Childhood growth hormone treatment: challenges, opportunities, and considerations.","volume":"8","author":"Tidblad","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"R24-20260831","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5664\/jcsm.27601","article-title":"Sleep disordered breathing in infants with Prader-Willi syndrome during the first 6 weeks of growth hormone therapy: a pilot study.","volume":"5","author":"Miller","year":"2009","journal-title":"J Clin Sleep Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:01:19Z","timestamp":1788195679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":24,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049264","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2026-03-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}